Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Pipeline Review, H2 2017

Metabotropic Glutamate Receptor 4 Pipeline Review Metabotropic Glutamate Receptor 4 Pipeline Review

Albany, US, 2017-Jul-28 — /EPR Network/ — Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 4 – Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request Free Sample Report – http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256885

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinson’s Disease, Anxiety Disorders, Autism, Depression, Drug Addiction, Infantile Spasm (West Syndrome), Multiple Sclerosis, Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse Full Report with TOC – http://www.marketresearchhub.com/report/metabotropic-glutamate-receptor-4-gprc1d-or-mglur4-or-grm4-pipeline-review-h2-2017-report.html

Scope

– The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
– The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects
– The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry – http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1256885

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at – https://www.industrynewsanalysis.com/

Matched content

Editor’s pick

Express Press Release Distribution